Optimal use of biologics in the management of Crohn's disease

Therapeutic Advances in Gastroenterology

Volumn 3, Issue 3, 2010, Pages 179-189

  Panaccione, Remo ^a   Ghosh, Subrata ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adalimumab; Biologic therapy; Certolizumab; Crohn's disease; Infliximab; Natalizumab; Prognostic factors

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB;

BIOLOGICAL THERAPY; CHRONIC DISEASE; CLINICAL TRIAL; CROHN DISEASE; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATION; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW;

EID: 77953426085     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09357579     Document Type: Review

References (47)

1. Allez, M., Lemann, M., Bonnet, J., Cattan, P., Jian, R. and Modigliani, R. ( 2002) Long-term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 97: 947-953.
2. Baert, F., Noman, M., Vermeire, S., van Assche, G., D’ Haens, G., Carbonez, A. et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601-608.
3. Beaugerie, L., Seksik, P., Nion-Larmurier, I., Gendre, J.P. and Cosnes, J. ( 2006) Predictors of Crohn's disease. Gastroenterology 130: 650-656.
4. Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R. et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 132: 52-65.
5. de Silva, S., Kaplan, G. and Panaccione, R. ( 2008) Sequential therapies for Crohn's disease: Optimizing conventional and biologic strategies. Rev Gastroenterol Disord 8: 109-116.
6. D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H. et al. (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial. Lancet 371: 660-667.
7. Dubinsky, M.C., Lin, Y.C., Dutridge, D., Picornell, Y., Landers, C.J., Farrior, S. et al. (2006) Serum immune responses predict rapid disease progression among children with Crohn's disease: Immune responses predict disease progression. Am J Gastroenterol 101: 360-367.
8. Faubion, J.W.A., Loftus, Jr E.V., Harmsen, W.S., Zinsmeister, A.R. and Sandborn, W.J. ( 2001) The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 121: 255-261.
9. Feagan, B.G., McDonald, J., Panaccione, R., Enns, R., Bernstein, C., Ponich, T. et al. (2008) A randomized, placebo-controlled study to evaluate the efficacy of infliximab in combination with methotrexate for the long-term treatment of Crohn's disease. Gastroenterology 134(4 Suppl 1): Presented Late Breaking Abstract 682C.
10. Hanauer, S.B., D'Haens, G.R. and Colombel, J.F. ( 2006b) Sustained clinical remission in patients with moderate to severe Crohn's disease with adalimumab, regardless of anti-TNF history or concomitant immunosuppressant therapy. Am J Gastroenterol 101: S457. Abstract 1173.
11. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F. et al. (2002) Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359: 1541-1549.
12. Hanauer, S.B. and Sandborn, W. for the Practice Parameters Committee of the American College of Gastroenterology. (2001) Management of Crohn's disease in adults. Am J Gastroenterol 96: 635-643.
13. Hanauer, S.B., Sandborn, W.J., Rutgeerts, P., Fedorak, R.N., Lukas, M., MacIntosh, D. et al. (2006 a) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 130: 323-333.
14. Hanauer, S.B., Wagner, C.L., Bala, M., Mayer, L., Travers, S., Diamond, R.H. et al. (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2: 542-553.
15. Hyams, J., Crandall, W., Kugathasan, S., Griffiths, A., Olson, A., Johanns, J. et al. for The REACH Study Group. ( 2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132: 863-873.
16. Lémann, M., Mary, J.Y., Duclos, B., Veyrac, M., Dupas, J.L., Delchier, J.C. et al. for the Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). (2006 ) Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: A randomized placebo-controlled trial. Gastroenterology 130: 1054-1061.
17. Lichtenstein, G., Diamond, R.H. and Wagner, C. ( 2007) Infliximab administered as 3-dose induction followed by scheduled maintenance therapy in IBD: Comparable clinical outcomes with or without concomitant immunomodulators. Gastroenterology 132(Suppl 2): A146. Abstract 982.
18. Lichtenstein, G.R., Mitchev, K. and D'Haens, G. ( 2008) Re-induction with certolizumab pegol following disease exacerbation during maintenance therapy is effective to regain response and remission. Gastroenterology 2008; 133: A488. Abstract T1120.
19. Lofberg, R., Louis, E. and Reinisch, W. ( 2008) Adalimumab effectiveness in TNF-antagonist-naive patients and in infliximab nonresponders with Crohn's disease: Results from the CARE study. Am J Gastroenterol 103: 1069.
20. Maser, E.A., Villela, R., Silverberg, M.S. and Greenberg, G.R. ( 2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 4: 1248-1254.
21. Mozziconacci, N., Vermeire, S. and Laharie, D. ( 2008) Efficacy of a third Anti-TNF monoclonal antibody in Crohn's disease after a failure of two other anti-TNFs. Gastroenterology 134: A663. Abstract W1244.
22. Munkholm, P., Langholz, E., Davidsen, M. and Binder, V. ( 1994) Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35: 360-362.
23. Panaccione, R., Sandborn, W., Colombel, J.-F., Targan, S. and Lashner, B. ( 2004) Efficacy assessment of natalizumab in patients with Crohn's disease and prior history of infliximab therapy: Results from ENACT-2. Am J Gastroenterol 99(Suppl 2): A30.
24. Panaccione, R., Sandborn, W.J., D'Haens, G., Colombel, J., Rutgeerts, P. and Pollock, P. ( 2008a) Adalimumab maintains long-term remission in moderately to severely active Crohn's disease after infliximab failure: 1-year follow-up of CHARM trial. Gastroenterology 134: A-133. Abstract 919.
25. Panaccione, R., Sandborn, W.J., D'Haens, G., Colombel, J., Rutgeerts, P. and Pollock, P. ( 2008b) Adalimumab maintains long-term remission in moderately to severely active Crohn's disease after infliximab failure: 1-year follow-up of GAIN trial. Gastroenterology 134: A-133. Abstract 920.
26. Panaccione, R., Sandborn, W.J., Pollack, P.F., Chen, N., Chao, J. and Mulani, P. ( 2008c) 12-week response to adalimumab among initial week-4 nonresponders in patients with Crohn's disease. Gut 57(Suppl II): A259.
27. Present, D.H., Rutgeerts, P., Targan, S., Hanauer, S.B., Mayer, L., van Hogezand, R.A. et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398-1405.
28. Regueiro, M., Siemanowski, B., Kip, K.E. and Plevy, S. ( 2007) Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 13: 1093-1099.
29. Rutgeerts, P., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F. et al. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126: 402-413.
30. Sandborn, W.J., Colombel, J.F., Enns, R., Feagan, B.G., Hanauer, S.B., Lawrance, I.C. et al. for the International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group and Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912-1925.
31. Sandborn, W.J., Colombel, J.F., Rutgeerts, P., Mulani, P., Panaccione, R., Lomax, K. et al. (2008 a) Benefits of dosage adjustment with adalimumab in Crohn's disease: An analysis of the CHARM trial. Gastroenterology 134: A-347. Abstract M1143.
32. Sandborn, W.J., Feagan, B.G., Stoinov, S., Honiball, P.J., Rutgeerts, P., Mason, D. et al. for the PRECISE 1 Study Investigators. ( 2007c) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228-238.
33. Sandborn, W.J., Hanauer, S.B., Rutgeerts, P., Fedorak, R.N., Lukas, M., MacIntosh, D.G. et al. (2007 a) Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 56: 1232-1239.
34. Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Colombel, J.F., Panaccione, R. et al. (2007 b) Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann Intern Med 146: 829-838.
35. Sandborn, W., Rutgeerts, P., Reinishch, W., Mantzaris, G., Kornbluth, A., Rachmilewetz, D. et al. (2008 b) SONIC: A randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Am J Gastroenterol 103: 1117. Late-breaking abstract 29.
36. Sands, B.E., Anderson, F.H., Bernstein, C.N., Chey, W.Y., Feagan, B.G., Fedorak, R.N. et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876-885.
37. Schreiber, S., Hanauer, S.B., Lichtenstein, G.R. and Sandborn, W.J. ( 2007a) Superior efficacy of certolizumab pegol in early Crohn's disease is independent of CRP status. Gastroenterology 132(4 Suppl 1): A510-A511. Abstract T1298.
38. Schreiber, S., Khaliq-Kareemi, M., Lawrance, I.C., Thomsen, O., Hanauer, S.B., McColm, J. et al. for the PRECISE 2 Study Investigators. ( 2007b) Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357: 239-250.
39. Schreiber, S., Reinisch, W., Colombel, J., Sandborn, W.J., Panaccione, R., Mulani, P. et al. (2007 c) Early Crohn's disease shows high levels of remission to therapy with adalimumab: Sub-analysis of CHARM. Gastroenterology 132(4 Suppl 1): A147. Abstract 985.
40. Targan, S.R., Feagan, B.G., Fedorak, R.N., Lashner, B.A., Panaccione, R., Present, D.H. et al. for the International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. ( 2007) Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology 132: 1672-1683.
41. Targan, S.R., Hanauer, S.B., van Deventer, S.J., Mayer, L., Present, D.H., Braakman, T. et al. (1997) A short-term study of chimeric monoclonal antibody cA 2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA 2 Study Group. N Engl J Med 337: 1029-1035.
42. Travis, S.P., Stange, E.F., Lémann, M., Oresland, T., Chowers, Y., Forbes, A. et al. for the European Crohn's and Colitis Organisation. (2006) European evidence based consensus on the diagnosis and management of Crohn's disease: Current management. Gut 55: i16-i35.
43. van Assche, G., Magdelaine-Beuzelin, C., D'Haens, G., Baert, F., Noman, M., Vermeire, S. et al. (2008) Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: A randomized trial. Gastroenterology 134: 1861-1868.
44. Vermeire, S., Abreu, M.T. and D'Haens, G. ( 2008) Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: Open-label induction preliminary results of the WELCOME study. Gastroenterology 134: A-67.
45. Vermeire, S., Noman, M., van Assche, G., Baert, F., D'Haens, G. and Rutgeerts, P. ( 2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56: 1226-1231.
46. Wolf, D., Colombel, J.-F., Enns, R., Feagan, B., Fedorak, R., Panaccione, R. et al. (2007) Natalizumab does not require the concomitant use of immunosuppressants for the induction of sustained response and remission in Crohn's disease. Am J Gastroenterol 102(Suppl 2): 1025.
47. Yousry, T.A., Major, E.O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J. et al. (2006) Evaluation patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924.